Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · IEX Real-Time Price · USD
13.89
-0.23 (-1.63%)
At close: Jul 2, 2024, 4:00 PM
13.35
-0.54 (-3.89%)
After-hours: Jul 2, 2024, 5:49 PM EDT
Avadel Pharmaceuticals Employees
Avadel Pharmaceuticals had 154 employees as of December 31, 2023. The number of employees increased by 113 or 275.61% compared to the previous year.
Employees
154
Change (1Y)
113
Growth (1Y)
275.61%
Revenue / Employee
$358,058
Profits / Employee
-$1,018,403
Market Cap
1.34B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 154 | 113 | 275.61% |
Dec 31, 2022 | 41 | -25 | -37.88% |
Dec 31, 2021 | 66 | 34 | 106.25% |
Dec 31, 2020 | 32 | -18 | -36.00% |
Dec 31, 2019 | 50 | -94 | -65.28% |
Dec 31, 2018 | 144 | -36 | -20.00% |
Dec 31, 2017 | 180 | -12 | -6.25% |
Dec 31, 2016 | 192 | 83 | 76.15% |
Dec 31, 2014 | 109 | -142 | -56.57% |
Dec 31, 2013 | 251 | -5 | -1.95% |
Dec 31, 2012 | 256 | -11 | -4.12% |
Dec 31, 2011 | 267 | -24 | -8.25% |
Dec 31, 2010 | 291 | -11 | -3.64% |
Dec 31, 2009 | 302 | 18 | 6.34% |
Dec 31, 2008 | 284 | -18 | -5.96% |
Dec 31, 2007 | 302 | -4 | -1.31% |
Dec 31, 2006 | 306 | 47 | 18.15% |
Dec 31, 2005 | 259 | 35 | 15.63% |
Dec 31, 2004 | 224 | 50 | 28.74% |
Dec 31, 2003 | 174 | 24 | 16.00% |
Dec 31, 2002 | 150 | 12 | 8.70% |
Dec 31, 2001 | 138 | 1 | 0.73% |
Dec 31, 2000 | 137 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
U.S. Physical Therapy | 6,720 |
Tilray Brands | 1,600 |
Schrödinger | 867 |
Pacira BioSciences | 712 |
ANI Pharmaceuticals | 642 |
Arcus Biosciences | 577 |
Disc Medicine | 74 |
Belite Bio | 20 |
AVDL News
- 5 days ago - Avadel Pharmaceuticals to Join Russell 3000® Index - GlobeNewsWire
- 4 weeks ago - Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024 - GlobeNewsWire
- 6 weeks ago - Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 - GlobeNewsWire
- 3 months ago - Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference - GlobeNewsWire
- 4 months ago - Avadel Pharmaceuticals Issues Statement On Patent Litigation - GlobeNewsWire